Prionics is headquartered in Zurich, Switzerland, and has a major production facility in Lelystad, the Netherlands.
“Prionics adds a unique blend of expertise and diagnostic solutions to new and existing customers,” said Kirk Adams, global animal health leader. “Improved accessibility to animal testing benefits veterinarians and livestock producers.”
“Combining Prionics under the Life Technologies’ brand is certainly a win-win, since the products and capabilities are highly complementary,” said Dr Markus Moser, CEO of Prionics. “We believe this will have a strong and worldwide impact on the animal health industry.”
Prionics brings a state-of-the-art infrastructure along with a certified tuberculin manufacturing facility, plus additional enzyme-linked immunosorbent assays (ELISA) under the Life Technologies brand.
Source: Thermo Fisher Scientific
The completion of the transaction follows the receipt of all required regulatory approvals.
“We are pleased to announce that this transaction is now complete, and excited about our opportunity to create unrivalled leadership in serving research, life sciences, specialty diagnostics and applied markets,” said Marc N Casper, president and CEO of Thermo Fisher Scientific. “Our combined offering provides cutting-edge technologies such as genomics and proteomics to accelerate life sciences research and improve human health. And our complementary strengths in biosciences and bioprocessing will accelerate drug discovery, development and production.
“With the addition of Life Technologies, we are in an even stronger position to help our customers achieve their goals for innovation and productivity.”
© FoodBev Media Ltd 2024